Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

Leicester is the weight loss injection capital with almost 2,000 drugs prescribed each month, 6.8 times the proportion dished ...

First Amendment: Congress shall make no law respecting an establishment of religion, or prohibiting the free exercise thereof; or abridging the freedom of speech, or of the press; or the right of the ...

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

Eli Lilly (LLY) stock fell as its obesity therapy tirzepatide missed forecasts, amid focus on compounded weight loss ...

In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression of chronic ...

Wave received supportive initial feedback from FDA, who recognize the severity of HD and are receptive to and engaged with Wave regarding a potential pathway to accelerated approval. FDA is open to ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...